Paclitaxel pretreatment overcomes hypoxia inducible factor-1α-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells

Kun Goung Lai, Yi Hsien Lin, Chun Te Ho, Chun Yi Chen, Chu Ying Peng, Tsan Zon Liu, Jeng Fong Chiou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims This study delineated the mechanisms of paclitaxel (PTX) assistance in overcoming radioresistance in hepatoma and human lung adenocarcinoma (HLAC) cells. Main methods The TUNEL assay was used as an index of radiosensitivity, and the MTT assay assessed the efficacy of various combined PTX/RT treatments. The efficacy of PTX disruptions of hypoxia-inducible factor-1 alpha (HIF-1α) was assessed using Western blotting. Key findings Normoxically overexpressed HIF-1α in hepatoma J5 cells was mechanistically linked to activation of the bFGF/PI3K/Akt pathway because the viability of these cells was strongly inhibited by either Akt inhibitors or an HIF-1α inhibitor. All of the cell lines used were extremely sensitive to PTX, and these effects also correlated excellently with HIF-1α suppression. We designed five combined radiation-PTX protocols of varying dose duration and treatment sequences against CL1-1 cells based on the gathered data. Pretreatment of CL1-1 cells with PTX (100 nM) for 24 h before irradiation (2.5 Gy) was the best combined protocol to achieve maximum radiosensitizing effects. Significance Our data clearly indicate that PTX pretreatment is an effective radiosensitizing procedure against HIF-1α-expressing hepatoma and HLAC cells, which are constitutively endowed with radioresistance.

Original languageEnglish
Pages (from-to)7-12
Number of pages6
JournalLife Sciences
Volume136
DOIs
Publication statusPublished - Jul 11 2015

Fingerprint

Hypoxia-Inducible Factor 1
Paclitaxel
Hepatocellular Carcinoma
Assays
Cells
Radiation-Sensitizing Agents
Radiation Tolerance
In Situ Nick-End Labeling
Adenocarcinoma of lung
Phosphatidylinositol 3-Kinases
Dosimetry
Cell Survival
Western Blotting
Chemical activation
Irradiation
Radiation
Cell Line

Keywords

  • BFGF/PI3K/Akt pathway
  • HIF-1α
  • Paclitaxel
  • Radiosensitization

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Paclitaxel pretreatment overcomes hypoxia inducible factor-1α-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells. / Lai, Kun Goung; Lin, Yi Hsien; Ho, Chun Te; Chen, Chun Yi; Peng, Chu Ying; Liu, Tsan Zon; Chiou, Jeng Fong.

In: Life Sciences, Vol. 136, 11.07.2015, p. 7-12.

Research output: Contribution to journalArticle

Lai, Kun Goung ; Lin, Yi Hsien ; Ho, Chun Te ; Chen, Chun Yi ; Peng, Chu Ying ; Liu, Tsan Zon ; Chiou, Jeng Fong. / Paclitaxel pretreatment overcomes hypoxia inducible factor-1α-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells. In: Life Sciences. 2015 ; Vol. 136. pp. 7-12.
@article{62273d9b110a44a2be1f3b3eecd485cd,
title = "Paclitaxel pretreatment overcomes hypoxia inducible factor-1α-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells",
abstract = "Aims This study delineated the mechanisms of paclitaxel (PTX) assistance in overcoming radioresistance in hepatoma and human lung adenocarcinoma (HLAC) cells. Main methods The TUNEL assay was used as an index of radiosensitivity, and the MTT assay assessed the efficacy of various combined PTX/RT treatments. The efficacy of PTX disruptions of hypoxia-inducible factor-1 alpha (HIF-1α) was assessed using Western blotting. Key findings Normoxically overexpressed HIF-1α in hepatoma J5 cells was mechanistically linked to activation of the bFGF/PI3K/Akt pathway because the viability of these cells was strongly inhibited by either Akt inhibitors or an HIF-1α inhibitor. All of the cell lines used were extremely sensitive to PTX, and these effects also correlated excellently with HIF-1α suppression. We designed five combined radiation-PTX protocols of varying dose duration and treatment sequences against CL1-1 cells based on the gathered data. Pretreatment of CL1-1 cells with PTX (100 nM) for 24 h before irradiation (2.5 Gy) was the best combined protocol to achieve maximum radiosensitizing effects. Significance Our data clearly indicate that PTX pretreatment is an effective radiosensitizing procedure against HIF-1α-expressing hepatoma and HLAC cells, which are constitutively endowed with radioresistance.",
keywords = "BFGF/PI3K/Akt pathway, HIF-1α, Paclitaxel, Radiosensitization",
author = "Lai, {Kun Goung} and Lin, {Yi Hsien} and Ho, {Chun Te} and Chen, {Chun Yi} and Peng, {Chu Ying} and Liu, {Tsan Zon} and Chiou, {Jeng Fong}",
year = "2015",
month = "7",
day = "11",
doi = "10.1016/j.lfs.2015.06.006",
language = "English",
volume = "136",
pages = "7--12",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Paclitaxel pretreatment overcomes hypoxia inducible factor-1α-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells

AU - Lai, Kun Goung

AU - Lin, Yi Hsien

AU - Ho, Chun Te

AU - Chen, Chun Yi

AU - Peng, Chu Ying

AU - Liu, Tsan Zon

AU - Chiou, Jeng Fong

PY - 2015/7/11

Y1 - 2015/7/11

N2 - Aims This study delineated the mechanisms of paclitaxel (PTX) assistance in overcoming radioresistance in hepatoma and human lung adenocarcinoma (HLAC) cells. Main methods The TUNEL assay was used as an index of radiosensitivity, and the MTT assay assessed the efficacy of various combined PTX/RT treatments. The efficacy of PTX disruptions of hypoxia-inducible factor-1 alpha (HIF-1α) was assessed using Western blotting. Key findings Normoxically overexpressed HIF-1α in hepatoma J5 cells was mechanistically linked to activation of the bFGF/PI3K/Akt pathway because the viability of these cells was strongly inhibited by either Akt inhibitors or an HIF-1α inhibitor. All of the cell lines used were extremely sensitive to PTX, and these effects also correlated excellently with HIF-1α suppression. We designed five combined radiation-PTX protocols of varying dose duration and treatment sequences against CL1-1 cells based on the gathered data. Pretreatment of CL1-1 cells with PTX (100 nM) for 24 h before irradiation (2.5 Gy) was the best combined protocol to achieve maximum radiosensitizing effects. Significance Our data clearly indicate that PTX pretreatment is an effective radiosensitizing procedure against HIF-1α-expressing hepatoma and HLAC cells, which are constitutively endowed with radioresistance.

AB - Aims This study delineated the mechanisms of paclitaxel (PTX) assistance in overcoming radioresistance in hepatoma and human lung adenocarcinoma (HLAC) cells. Main methods The TUNEL assay was used as an index of radiosensitivity, and the MTT assay assessed the efficacy of various combined PTX/RT treatments. The efficacy of PTX disruptions of hypoxia-inducible factor-1 alpha (HIF-1α) was assessed using Western blotting. Key findings Normoxically overexpressed HIF-1α in hepatoma J5 cells was mechanistically linked to activation of the bFGF/PI3K/Akt pathway because the viability of these cells was strongly inhibited by either Akt inhibitors or an HIF-1α inhibitor. All of the cell lines used were extremely sensitive to PTX, and these effects also correlated excellently with HIF-1α suppression. We designed five combined radiation-PTX protocols of varying dose duration and treatment sequences against CL1-1 cells based on the gathered data. Pretreatment of CL1-1 cells with PTX (100 nM) for 24 h before irradiation (2.5 Gy) was the best combined protocol to achieve maximum radiosensitizing effects. Significance Our data clearly indicate that PTX pretreatment is an effective radiosensitizing procedure against HIF-1α-expressing hepatoma and HLAC cells, which are constitutively endowed with radioresistance.

KW - BFGF/PI3K/Akt pathway

KW - HIF-1α

KW - Paclitaxel

KW - Radiosensitization

UR - http://www.scopus.com/inward/record.url?scp=84936877810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936877810&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2015.06.006

DO - 10.1016/j.lfs.2015.06.006

M3 - Article

VL - 136

SP - 7

EP - 12

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -